Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
13 June 2013 -- Vernalis plc today announces that data from a recent study of frovatriptan alone and in combination with dexketoprofen will be presented at the International Headache Congress, which is being held in Boston from 27 to 30 June 2013.
The data, from a pilot study conducted in Italy in 314 subjects, sponsored by Menarini International Operations Luxembourg which markets frovatriptan in Europe and dexketoprofen in multiple regions, will be presented in the form of two posters and discussion sessions. The first, to be presented by Dr Tullo (National Neurological Institute Carlo Besta, Milan), will outline the efficacy and safety data from the entire study population and the second (presented by Dr Allais, University of Turin) will describe the outcome in a pre-defined sub-set of patients with menstrual migraine.
The two posters will be on display from the morning of Thursday 27th June until the afternoon of Saturday 29th June, with discussion sessions on Friday 28th (10.30 to 12.00 and 15.45 to 16.45) and Saturday 29th (15.45 to 16.45).
Abstract 450300 / Poster P17
Comparison of Frovatriptan Plus Dexketoprofen (25 mg or 37.5 mg) Versus Frovatriptan Alone in the Treatment of Migraine Attacks with or without Aura: A Pilot Study
Abstract 450282 / Poster P228
Efficacy and Safety of Frovatriptan+Dexketoprofen in Menstrual Related Migraine (MRM)
Enquiries:
Vernalis Contacts:
Ian Garland, Chief Executive Officer +44 (0) 118 938 0015 David Mackney, Chief Financial Officer
Nomura Code Securities Limited: +44 (0) 20 7776 1200
Juliet Thompson
Jonathan Senior
Brunswick Group: +44 (0) 20 7404 5959
Jon Coles
About Vernalis
Vernalis is a revenue generating development stage pharmaceutical company with significant expertise in drug development. The Group has one marketed product, frovatriptan for the acute treatment of migraine, an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as seven programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company’s technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris.
For further information about Vernalis, please visit www.vernalis.com
Vernalis Forward-Looking Statement
This news release may contain forward-looking statements that reflect the Company’s current expectations regarding future events including the clinical development and regulatory clearance of the Company’s products, the Company’s ability to find partners for the development and commercialisation of its products, as well as the Company’s future capital raising activities. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion of clinical studies, the uncertainties related to the regulatory process, the ability of the Company to identify and agree beneficial terms with suitable partners for the commercialisation and/or development of its products, as well as the achievement of expected synergies from such transactions, the acceptance of frovatriptan and other products by consumers and medical professionals, the successful integration of completed mergers and acquisitions and achievement of expected synergies from such transactions, and the ability of the Company to identify and consummate suitable strategic and business combination transactions.
Help employers find you! Check out all the jobs and post your resume.
